A5016694830- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Rheumatoid Arthritis Research and Therapies
- Urticaria and Related Conditions
- Dermatological and COVID-19 studies
- Colorectal Cancer Treatments and Studies
- Systemic Lupus Erythematosus Research
- Viral Infections and Immunology Research
- Cutaneous Melanoma Detection and Management
- Smoking Behavior and Cessation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Advancements in Transdermal Drug Delivery
- melanin and skin pigmentation
- Acne and Rosacea Treatments and Effects
- Dermatologic Treatments and Research
- Sleep and Wakefulness Research
- Extracellular vesicles in disease
- Retinal and Optic Conditions
- Drug-Induced Adverse Reactions
- Inflammasome and immune disorders
- Autoimmune and Inflammatory Disorders
- Cell Image Analysis Techniques
- Chemotherapy-related skin toxicity
- Dermatology and Skin Diseases
- Vascular Anomalies and Treatments
Women's College Hospital
2024
University of Toronto
2024
Hôpital Saint-Louis
2017-2019
Assistance Publique – Hôpitaux de Paris
2009-2019
Hôpital Bichat-Claude-Bernard
2008-2015
Université Claude Bernard Lyon 1
2015
Université Paris-Saclay
2009
Délégation Paris 7
2008
Hôpital Paul-Brousse
2004
Fixed drug eruption (FDE) is one of the most typical cutaneous adverse reactions. This localized drug-induced reaction characterized by its relapse at same sites. Few large series FDE are reported. The aim this study was to retrospectively collect and analyse well informed cases observed in a hospital setting. involved 17 academic clinical centers. A French nation-wide retrospective multicentric carried out on 3-year-period from 2005 2007 collecting data seventeen departments dermatology...
View Large Image Figure ViewerDownload Hi-res image Download (PPT) The widespread severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has given rise to COVID-19 and its devastating consequences. Research studies report frequent dermatological manifestations, with at least 20% of patients having cutaneous lesions (Magro et al., 2021Magro C. Nuovo G. Mulvey J.J. Laurence J. Harp Crowson A.N. skin as a critical window in unveiling the pathophysiologic principles COVID-19.Clin...
6681 Background: To determine, from two consecutive phase II studies, the efficacy of oxaliplatin (L-OHP), cytarabine (ara-C), and dexamethasone (DHAOx), DHAOx plus rituximab (R-DHAOx), in patients with non-Hodgkin's lymphoma (NHL). Methods: In Study I, treatment consisted (dexamethasone, 40 mg/day, days 1 to 4; L-OHP, 130 mg/m2, day 1; ara-C, 2,000 every 12 hrs, 2). II, R-DHAOx (DHAOx rituximab, on 1, 375 mg/m2). Courses were repeated 21 days. Patients had failed achieve a complete response...
6681 Background: To determine, from two consecutive phase II studies, the efficacy of oxaliplatin (L-OHP), cytarabine (ara-C), and dexamethasone (DHAOx), DHAOx plus rituximab (R-DHAOx), in patients with non-Hodgkin's lymphoma (NHL). Methods: In Study I, treatment consisted (dexamethasone, 40 mg/day, days 1 to 4; L-OHP, 130 mg/m2, day 1; ara-C, 2,000 every 12 hrs, 2). II, R-DHAOx (DHAOx rituximab, on 1, 375 mg/m2). Courses were repeated 21 days. Patients had failed achieve a complete response...
20748 Background: Cetuximab (Cetux) is an anti-EGFR monoclonal IgG1 antibody with proven activity both as a single agent or in combination chemotherapy against metastatic colorectal cancer (MCC). Approximately 3% of severe IRR occur, especially during the first minutes infusion, despite only recommended antihistamine premedication, preventing further administration. We sought 1/ to reduce occurrence through improved premedication and 2/ decrease drug wasting costs original pharmaceutical...